Market Closed -
Singapore S.E.
02:35:01 09/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
1.36
SGD
|
0.00%
|
|
-2.86%
|
-4.90%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
531.9
|
685.2
|
765.9
|
723.3
|
680.8
|
507
|
Enterprise Value (EV)
1 |
427.6
|
625.7
|
705.3
|
679.5
|
651.1
|
483.3
|
P/E ratio
|
15.3
x
|
24.1
x
|
31.3
x
|
29.2
x
|
26
x
|
18.4
x
|
Yield
|
6.11%
|
4.97%
|
2.88%
|
3.08%
|
3.46%
|
3.85%
|
Capitalization / Revenue
|
5.32
x
|
6.61
x
|
8.86
x
|
7.17
x
|
6.29
x
|
4.53
x
|
EV / Revenue
|
4.27
x
|
6.03
x
|
8.16
x
|
6.74
x
|
6.01
x
|
4.32
x
|
EV / EBITDA
|
11.1
x
|
15.5
x
|
24.1
x
|
19.4
x
|
17.1
x
|
12.4
x
|
EV / FCF
|
-241
x
|
20
x
|
55.2
x
|
52.9
x
|
73.7
x
|
40.3
x
|
FCF Yield
|
-0.42%
|
5.01%
|
1.81%
|
1.89%
|
1.36%
|
2.48%
|
Price to Book
|
3.53
x
|
5.22
x
|
5.7
x
|
5.68
x
|
5.54
x
|
3.87
x
|
Nbr of stocks (in thousands)
|
3,54,568
|
3,54,568
|
3,54,568
|
3,54,568
|
3,54,568
|
3,54,568
|
Reference price
2 |
1.500
|
1.932
|
2.160
|
2.040
|
1.920
|
1.430
|
Announcement Date
|
25/03/19
|
22/03/20
|
23/03/21
|
28/03/22
|
27/03/23
|
26/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
100.1
|
103.7
|
86.45
|
100.9
|
108.3
|
111.9
|
EBITDA
1 |
38.39
|
40.26
|
29.26
|
35.06
|
38.17
|
39.04
|
EBIT
1 |
31.97
|
34.19
|
23.69
|
29.58
|
32.65
|
33.11
|
Operating Margin
|
31.95%
|
32.97%
|
27.4%
|
29.32%
|
30.15%
|
29.59%
|
Earnings before Tax (EBT)
1 |
41.14
|
34.93
|
29.38
|
30.37
|
32.55
|
34.07
|
Net income
1 |
34.7
|
28.41
|
24.49
|
24.78
|
26.18
|
27.6
|
Net margin
|
34.68%
|
27.4%
|
28.33%
|
24.56%
|
24.18%
|
24.67%
|
EPS
2 |
0.0979
|
0.0801
|
0.0691
|
0.0699
|
0.0738
|
0.0778
|
Free Cash Flow
1 |
-1.776
|
31.34
|
12.77
|
12.84
|
8.84
|
11.99
|
FCF margin
|
-1.77%
|
30.22%
|
14.77%
|
12.72%
|
8.16%
|
10.71%
|
FCF Conversion (EBITDA)
|
-
|
77.83%
|
43.65%
|
36.62%
|
23.16%
|
30.7%
|
FCF Conversion (Net income)
|
-
|
110.3%
|
52.13%
|
51.81%
|
33.76%
|
43.43%
|
Dividend per Share
2 |
0.0916
|
0.0960
|
0.0622
|
0.0628
|
0.0664
|
0.0550
|
Announcement Date
|
25/03/19
|
22/03/20
|
23/03/21
|
28/03/22
|
27/03/23
|
26/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
104
|
59.5
|
60.6
|
43.8
|
29.7
|
23.7
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.78
|
31.3
|
12.8
|
12.8
|
8.84
|
12
|
ROE (net income / shareholders' equity)
|
23.4%
|
20.3%
|
18.7%
|
19.1%
|
21.1%
|
21.8%
|
ROA (Net income/ Total Assets)
|
10.8%
|
10.8%
|
7.17%
|
9.07%
|
10.6%
|
10.8%
|
Assets
1 |
321.1
|
262.8
|
341.6
|
273.1
|
248.1
|
256.5
|
Book Value Per Share
2 |
0.4300
|
0.3700
|
0.3800
|
0.3600
|
0.3500
|
0.3700
|
Cash Flow per Share
2 |
0.2900
|
0.2600
|
0.2600
|
0.2100
|
0.1700
|
0.1600
|
Capex
1 |
26.2
|
5.37
|
15
|
12.3
|
8.91
|
12.8
|
Capex / Sales
|
26.18%
|
5.18%
|
17.35%
|
12.17%
|
8.23%
|
11.43%
|
Announcement Date
|
25/03/19
|
22/03/20
|
23/03/21
|
28/03/22
|
27/03/23
|
26/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -4.90% | 356M | | 0.00% | 7.15B | | -10.21% | 2.96B | | -9.02% | 2.8B | | -28.49% | 1.77B | | +4.06% | 1.24B | | -5.75% | 1.06B | | -9.64% | 834M | | -8.98% | 820M | | -3.23% | 771M |
Testing Laboratories
|